











































Disease severity-associated gene expression in canine
myxomatous mitral valve disease is dominated by TGFß
signalling
Citation for published version:
Markby, G, MacRae, V, Summers, K & Corcoran, B 2020, 'Disease severity-associated gene expression in
canine myxomatous mitral valve disease is dominated by TGFß signalling', Frontiers in genetics.
https://doi.org/10.3389/fgene.2020.00372
Digital Object Identifier (DOI):
10.3389/fgene.2020.00372
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright © 2020 Markby, Macrae, Summers and Corcoran. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
fgene-11-00372 April 27, 2020 Time: 18:40 # 1
ORIGINAL RESEARCH




University of Texas MD Anderson
Cancer Center, United States
Reviewed by:
Georges Nemer,
American University of Beirut,
Lebanon
Priyanka Baloni,












This article was submitted to
Systems Biology,
a section of the journal
Frontiers in Genetics
Received: 17 December 2019
Accepted: 26 March 2020
Published: 27 April 2020
Citation:
Markby GR, Macrae VE,
Summers KM and Corcoran BM
(2020) Disease Severity-Associated
Gene Expression in Canine
Myxomatous Mitral Valve Disease Is




Expression in Canine Myxomatous
Mitral Valve Disease Is Dominated by
TGFβ Signaling
Greg R. Markby1, Vicky E. Macrae1, Kim M. Summers1† and Brendan M. Corcoran1,2*
1 The Roslin Institute, University of Edinburgh, Scotland, United Kingdom, 2 Royal Dick, School of Veterinary Studies,
University of Edinburgh, Scotland, United Kingdom
Myxomatous mitral valve disease (MMVD) is the most common acquired canine
cardiovascular disease and shares many similarities with human mitral valvulopathies.
While transcriptomic datasets are available for the end-stage disease in both species,
there is no information on how gene expression changes as the disease progresses,
such that it cannot be stated with certainty if the changes seen in end-stage disease
are casual or consequential. In contrast to humans, the disease in dogs can be more
readily examined as it progresses, and this allows an opportunity for insight into disease
pathogenesis relevant to both species. The aim of this study was to identify changes in
valve gene expression as canine MMVD advances over an entire life-time, from normal
(grade 0) to severely affected (grade 4), and differences in gene expression comparing
normal and disease areas of the same valve. Transcriptomic profiling identified 1002
differentially expressed genes (DEGs) across all four disease grades when compared
with normal valves with the greatest number of DEGs in grade 3 (673) and grade 4 (507).
DEGs were associated with a large number of gene families, including genes encoding
cytoskeletal filaments, peptidases, extra-cellular matrix (ECM) proteins, chemokines and
integrins. Gene enrichment analysis identified significant grade-dependent changes in
gene clustering, with clusters trending both up and down as disease progressed.
Significant grade-dependent changes in hallmark disease gene expression intensity
were identified, including ACTA2, HTR2B, MMP12, and CDKN2A. Gene Ontology terms
were dominated by terms for ECM and inflammation with TGFβ1, TNF, IFGN identified
as the top up-stream regulators in both whole and dissected diseased valve samples.
These data show that while disease progression in MMVD is associated with increasing
numbers of DEGs, TGFβ appears to be the dominant signaling pathway controlling
pathogenesis irrespective of disease severity.
Keywords: myxomatous mitral valve disease, gene expression, canine, transforming growth factor β, ontogeny
gene expression
INTRODUCTION
Myxomatous mitral valve disease (MMVD) is the single most common acquired cardiovascular
disease of the dog and shares similarities with several human mitral valvulopathies including
Barlow’s Disease (BD) and fibroelastic deficiency (FED) (Buchanan, 1977; Han et al., 2010; Levine
et al., 2015; Markby G. R. et al., 2017). The disease in the dog is characterized by its ubiquity,
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such that all dogs will eventually develop some evidence of the
disease, and there is a close relationship between age and disease
severity (Han et al., 2010, 2013). Several pedigree breeds have a
heightened susceptibility to develop the disease sooner, progress
more rapidly and become more severely affected (Beardow and
Buchanan, 1993; Stern et al., 2015; Lu et al., 2016). While
familial valvulopathies are also found in human patients, non-
syndromic BD seems to show the closest parallels with canine
MMVD as it becomes apparent between the fourth and sixth
decade, but the exact prevalence in the younger adult population
is unknown (Levine et al., 2015; Markby G. R. et al., 2017;
Gasser et al., 2018).
There are a limited number of studies looking at valve gene
expression in both canine and human mitral valve tissue (Oyama
and Chittur, 2006; Hulin et al., 2012; Sainger et al., 2012; Li et al.,
2015a; Lu et al., 2015b; Thalji et al., 2015; Greenhouse et al.,
2016). All have examined expression in elderly individuals with
severe disease [euthanased because of intractable heart failure
(dog); patients requiring valve surgery (human)], and typically
compared to young normal adults (dog) or valves derived
from heart transplant recipients or donor hearts unsuitable for
transplantation (human). For the human diseases some have
reported exclusively for BD or FED or the disease has not been
indicated (Sainger et al., 2012; Thalji et al., 2015; Greenhouse
et al., 2016). For both species, there are major limitations in
developing studies that examine age-matched cohorts.
There are no data on how gene expression patterns change
as the disease develops, and it is not possible to say if gene
expression changes are causal or consequential. An additional
confounding factor is that in severe end-stage BD and FED,
but not canine MMVD, there is marked fibrosis surrounding
the central myxomatous core of the valve, such that pro-fibrotic
(TGFβ1-dependent) signaling pathways dominate human valve
transcriptomic data (McDonald et al., 2002; Han et al., 2010;
Sainger et al., 2012; Roberts et al., 2014; Thalji et al., 2015;
Greenhouse et al., 2016). In the early stages of BD, fibrosis is
not present and the primary pathological change of myxomatous
degeneration is similar to that seen in the dog. For dog studies, the
whole valve gene expression has been reported, while in human
studies the gene expression of the severely diseased portion
respected during surgery (typically posterior valve cusp P2) has
been described, but no studies have reported gene expression
in overtly diseased areas compared to normal areas within the
same mitral valve in either species (Oyama and Chittur, 2006;
Sainger et al., 2012; Lu et al., 2015b; Thalji et al., 2015). However,
a valve dissection approach has been successfully used to identify
severity-dependent gene changes in human calcific aortic valve
(Nagy et al., 2011).
While varying numbers of differentially expressed genes
(DEGs) have been reported for the dog and human, there are
shared changes based on gene ontology and KEGG pathway
analysis, such as for ECM, cell signaling and movement,
cardiovascular development, inflammation and endothelial-to-
mesenchymal transition (EndoMT) (Oyama and Chittur, 2006;
Sainger et al., 2012; Li et al., 2015b; Lu et al., 2015b; Thalji
et al., 2015; Greenhouse et al., 2016; Markby G. R. et al.,
2017). There are some variations, such that inflammation and
EndoMT gene changes are more prominent in the dog mitral
valve, while heightened TGFβ1 signaling with activation of
canonical SMAD signaling is more prominent in the human
valve (Oyama and Chittur, 2006; Sainger et al., 2012; Hagler
et al., 2013; Li et al., 2015a; Lu et al., 2015a,b; Thalji et al.,
2015; Greenhouse et al., 2016). The dog and human do
share increased expression of 5HT receptor genes and changes
in serotonergic signaling pathways, but changes in a range
of metalloproteinases, including MMPs and ADAMTS family
members, are both variable and inconsistent across both species
(Oyama and Chittur, 2006; Disatian and Orton, 2009; Lu et al.,
2015b; Thalji et al., 2015). In the human valve there is evidence
of oxidative stress with increased NOX gene expression and
down-regulation of metallothionein genes, but this has not been
reported in the dog (Sainger et al., 2012; Lu et al., 2015b;
Thalji et al., 2015).
With more ready access to valves from dogs compared to
humans, and with varying degrees of pathology and relatively
close age-dependency, it is possible to examine the ontogeny of
the myxomatous valve gene expression profile over the entire
lifetime. This would allow insight into the signaling pathways
associated with MMVD pathogenesis, those gene changes that
are a consequence of advancing pathology, and potentially those
that are limiting the development of valve fibrosis (Lu et al.,
2015b; Thalji et al., 2015). Examining the dog might give insight
into the drivers of myxomatous degeneration in BD patients
prior to the development of secondary fibrosis. For both species,
understanding the early drivers of pathogenesis would allow
identification of novel therapeutic targets to slow or arrest
disease progression.
The aims of this study, therefore, were to examine changes
in valve gene expression as MMVD develops over the entire
lifetime of the dog, and to compare gene expression in overtly
myxomatous areas with adjacent normal areas. Overall these data
would give unique insight into the temporal and spatial valve
gene expression in MMVD.
MATERIALS AND METHODS
Tissue Samples
Valves were collected from 41 dogs within 15–30 min
after euthanasia (intravenous pentobarbitone over-dose) and
immediately placed in RNAlater (Invitrogen, United States).
Valves were collected with full owner consent and according
to institutional ethical guidelines [R(D) SVS Veterinary Ethics
Research Committee] and no animals were euthanased for the
purpose of the study. The grade of MMVD was determined
independently by two of the authors (GM, BC) using the Whitney
system; grade 0 (normal) to grade 4 (severely affected) (Whitney,
1974). Six samples for each grade of disease were collected for
whole valve gene analysis. A further seven grade 2 valves were
processed in the same manner and underwent micro-dissection
separating diseased from normal regions. To account for possible
regional gene differences, and since pathology is predominantly
found at the valve edge, four additional normal dog valves were
also dissected in the same manner as a control group.
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RNA Extraction, Quantification, Quality,
and Transcriptomic Profiling
For the whole valves anterior and posterior leaflets were
combined and processed for RNA extraction. A standard
tissue RNA extraction protocol was used for all samples,
as previously described (Lu et al., 2015b; Tan et al., 2019).
Briefly, the Qiagen RNeasy mini kit (Qiagen, Germany) was
used for RNA extraction and DNA removal, and RNA was
quantified by spectrophotometry in a NanoDropTM1000 (Thermo
Scientific). Degradation was assessed using the Agilent RNA
Screentape system and Agilent 2200 tapestation analyzer (Agilent
Technologies, United States) to determine the ratio of ribosomal
28S–18S RNA and generate an RNA integrity number (RIN).
Affymetrix Canine Gene 1.1 Sense Target
(ST) Microarray Analysis
The Affymetrix GeneChipTM Canine Gene 1.1 ST Array plate
(Affymetrix, United States) for transcriptomic profiling was used
to quantify RNA levels in the different samples (performed
by Edinburgh Genomics). Resulting CEL files were opened in
the Affymetrix expression console (version 1.4.1.46) using the
canine 1.1ST library files from Affymetrix. Robust Multi-array
Average (RMA) was used to perform gene-level normalization
and signal level summarization. Quality control assessment on
the data set included hybridization (spike in) controls, labeling
(poly-A) controls and area under the curve (AUC) control, probe
cell intensity boxplots, a signal histogram graph and principle
component analysis (PCA) plot. The datasets were then exported
with annotation as a text file used for the network analysis and as
CHP files.
The CHP files were uploaded to the Affymetrix transcriptome
analysis console (TAC; version 3.1.0.5) which was used to
perform paired or unpaired one-way analysis of variance
(ANOVA) (Tan et al., 2019). The DEG lists were created based on
P-value< 0.05, log2 signal intensity>2.8 or>3.8 and fold change
of >1.5 or <−1.5. Where possible Benjamini Hochberg false
discovery rate (FDR) correction (Q-value < 0.05) was applied to
derived data sets.
Algorithm information for un-annotated transcript probes
was found in TAC through an interface with the Affymetrix
online browser. Probe sequence was copied and BLAST analysis
performed on the online browser at http://www.ensembl.org to
manually match the probe to a transcript. A transcript was
considered matched to a probe sequence and could be manually
annotated when the E-score was< 1× 10−20 and other suggested
transcripts did not meet these criteria. Gene lists were then used
for gene enrichment analysis.
Microarray Validation
Standard RT-qPCR, with the Takyon 2X low Rox SYBR green
mastermix dTTP blue (Eurogentec, Belgium), was used to
validate the microarray results, and the genes selected were a
combination of recognized disease markers (ACTA2, HTR2B),
metalloproteinases (MMP12, ADAMTS5, ADAMTS19) and
genes found to be highly up-regulated in the microarray data
sets (see Results; SLC10A6, CDKN2A, ACTG2, SLIT3, and
CILP). MRPS25, GAPDH, and RPL32 were the reference genes
(Supplementary Table S1). The CanFam 3.1 genome assembly1
was used, in combination with the primer3 browser-based primer
design tool,2 to identify primer sequences.
Gene Enrichment Analysis
Gene enrichment analysis used a combination of the
network analysis tools Graphia Pro 1.4 (formerly BioLayout
Express3D/Miru; Kajeka, United Kingdom3), Database for
Annotation, Visualization and Integrated Discovery (DAVID)4
and Ingenuity Pathway Analysis (IPA; Qiagen, Germany).
Graphia Pro 1.4 clusters nodes based on the similarity of gene
expression patterns and uses edges to indicate the correlation
between nodes, which represent, depending on the analysis,
either transcript-to-transcript or sample-to-sample analysis.
DAVID was used to predict biological processes and list gene
ontology (GO) terms and functional annotations, and IPA to




The whole valve cohort included 11 different breeds with 10
females and 20 males, and at least one female in each of the
grades. All cavalier King Charles spaniels (n = 8) had either
grade 3 or 4 disease. There was a significant difference in age
between grades, except when comparing normal to grade 1 and
grade 1 to grade 2. As expected there was a close association
between age (years ± S.E.) and grade of disease with normal
(3.0 ± 0.3), grade 1 (5.16 ± 0.9) and grade 2 (4.3 ± 0.58) dogs
typically less than 5 years old, and all grade 3 (11.0 ± 0.3) and
grade 4 (13.1 ± 0.6) dogs older than 10 years. Graphia Pro
1.4 sample-to-sample analysis and principal component analysis
(PCoA) identified the two samples with the lowest RIN clustering
away from the main group, and these were excluded from
further analysis (Supplementary Figures S1, S2). With those
outliers removed the Graphia Pro 1.4 sample-to-sample network
showed a distribution with normal and low-grade diseased valves
clustering away from the grades 3 and 4 diseased samples, and all
CKCSs samples clustering in grades 3 and 4, but did not identify
any effect of gender (Figure 1). Signal intensity distribution for
the remaining samples identified any genes expressed below 3.8
log2 signal intensity as likely the effect of background (unlogged
for Graphia pro analysis), and these were removed from further
analysis (Supplementary Figure S3).
In total 1002 genes (461 up-regulated, 541 down-regulated)
were differentially expressed (>1.5 or <1.5-fold change, p-value
< 0.05,>3.8 log2 signal intensity) in at least one grade of disease
when compared to normal valve samples. The volcano plots and
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FIGURE 1 | Sample-to-sample analysis using Graphia Pro 1.4. Each node
represents a sample, colored by grade of disease. Normal samples are
colored green, grade 1 brown, grade 2 black, grade 3 blue, and grade 4 red.
Edge color represents degree of correlation (red being stronger and blue
being weaker) above the assigned correlation coefficient cut off (r = 0.97).
Outliers have been removed.
RT-qPCR of the 10 selected genes showed the same direction
of change as the microarray results for the same genes, with five
increasing in diseased valves and five decreasing, and while there
were some differences in intensity of fold change, this validated
the microarray results (Figure 3 and Supplementary Table S2).
The data also illustrate specific gene examples of changes in
expression as disease developed.
The full gene lists are shown in Supplementary Tables S3–S6.
237 DEGs were shared between grades 3 and grade 4 valves,
all with the same direction of change and all with comparable
fold change except for LAMA2 (laminin;−5.51 vs.−1.83). Large
numbers of non-shared DEGs were from similar gene families
or paralogs of shared genes, such as ADAMs family peptidases,
chemokines, collagens and integrins. Comparing across all grades
only three transcripts were found differentially expressed in each
of the four data sets; CASP14 (caspase 14), LRRN1 (leucine rich
repeat neuronal 1) and miR218-1. Combining grades 1 and 2
datasets and comparing with either grades 3 and 4 together or
separately, 33 shared DEGs were identified. A small number of
microRNAs (miR) were found to be reduced in the different
diseased valve datasets, including miR218-1 in all four grades of
disease, miR328 in grades 1 and 2, and miR99A-1, miRLet-7C and
miR-491 in grades 3 and 4.
When the grades 3 and 4 datasets were examined, clear
functional themes in changes in gene expression were found,
including genes coding for cytoskeletal filaments, ADAM family
proteinases, cell cycle and apoptosis related proteins, collagens,
5HT receptors, basement membrane proteins and extracellular
matrix. Applying higher stringency analysis with an FDR Q-value
of < 0.1 identified 18 DEGs in grade 3 (12 up, 6 down) and 70 in
grade 4 (37 up, 33 down), but none were identified in grade 1 or 2
(Tables 1, 2). Comparing grades 3 and 4, applying the same FDR
value, NT5E (5-nucleotidase, ecto, also known as CD73; down),
several members of the CDKN family (cyclin-dependent kinase
inhibitors; up in grade 3 and down in grade 4) including two
probe sets targeted against CDKN2A and LRRN1 (leucine rich
repeat neuronal 1; up) were shared.
Transcript-to-transcript analysis of the average expression
per grade of the 1002 DEGs, using Graphia Pro 1.4, identified
expression differences across the grades. Twenty six clusters were
identified that were then examined for more specific trends
across all grades of disease (Figure 4). For the largest five
clusters the associated top 10 GO terms (DAVID 6.8) were
identified (Supplementary Table S7). Examples of GO terms
for clusters one to five included extracellular matrix (down
in diseased valves), immune response (up), G-protein coupled
receptor signaling (down), osteoblast and bone-related (up) and
metalloendopeptidase activity and stem cell differentiation (up).
For the 116 and 211 genes in the up- and down-regulated
clusters the average signal intensity changed by more than 2-
fold by grade 4.
For gene ontology enrichment (DAVID 6.8), without FDR,
the 10 top GO terms associated with increased or decreased
expression for each grade compared with normal are shown
in Supplementary Table S8. For grade 1, GO terms were
identified related to cell membrane, extracellular matrix and
calcium signaling. Only two GO terms were identified for
grade 2; negative regulation of growth and cellular response
to hormone stimulus. For grade 3 inflammatory response (up)
and proteinaceous extracellular matrix (down) were the top GO
terms, and for grade 4 these were neutrophil chemotaxis and
proteinaceous extracellular matrix Using only genes that met the
higher stringency FDR cut-off (q-value <0.1) only one GO term
was identified for grade 3 (negative regulation of inflammatory
response), but there were 19 significant GO terms for grade
4, with several of the same terms found in the less stringent
analysis, including positive regulation of the ERK1/2 cascade and
proteinaceous extracellular matrix (Supplementary Table S9).
IPA (for mapped genes without FDR correction applied)
identified a range of canonical pathways, with greatest overlap
between grades 3 and 4. The top three canonical pathways for
each grade are shown in Supplementary Table S10.
Upstream regulator analysis identified increasing numbers
of predicted transcriptional regulators as the disease progressed
and stronger association for the top up-stream regulators with
progressive worsening disease, includingTGFβ1,TNF, IFGN, and
LPS (Table 3). P2RY2, encoding for purinoceptor 2, was the top
up-stream regulator in grade 1. Forty five downstream target
genes of TGFβ1 and TNF signaling pathways were shared in
grade 4 samples (Supplementary Figure S4).
For each gene list, disease and functional annotations were
identified and the details for the top four for each grade
Frontiers in Genetics | www.frontiersin.org 4 April 2020 | Volume 11 | Article 372
fgene-11-00372 April 27, 2020 Time: 18:40 # 5
Markby et al. Canine Mitral Valve Disease Transcriptome
FIGURE 2 | Volcano plots of each stage of disease compared against transcript expression in normal valves. (A) Grade 1; (B) grade 2; (C) grade 3; (D) grade 4. The
X-axis shows fold change value and Y-axis shows the P-value. Central vertical line shows 0-fold change with negative fold changes relative to normal on the left and
positive fold changes on the right. Red are transcripts up-regulated in the diseased valves (>1.5-fold) green are down-regulated transcripts (<−1.5-fold) and gray
are transcripts which do not meet criteria for differential expression. Numbers for each category are shown in the table. Since some genes were differentially
expressed in more than one comparison the totals for unique genes are lower than the sum of the individual comparisons.
are shown in Supplementary Table S11. For one annotation
in each grade data set, representative examples of schematics
illustrating the inter-connection between the DEGs are shown
in Supplementary Figure S5. While the disease and functional
annotations differed somewhat between grades, shared themes
on cellular morphology, signaling, movement, death, survival and
proliferation and tissue development were apparent.
Overall, grades 3 and 4 had more credible statistical
changes and shared canonical pathways and up-stream regulators
compared to grades 1 and 2. Applying more stringent FDR
correction only grade 4 genes could be analyzed by IPA. Eighteen
canonical pathways were identified. In total 1201 molecules
were associated with the data set and TGFβ1 was the dominant
regulator. Five disease and function networks were identified
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FIGURE 3 | Microarray validation with RT-qPCR for selected genes. (A) Microarray fold change in gene expression intensity for each grade of disease, compared to
normal. (B) RT-qPCR fold change (normalized to GAPDH, MRPS25, and RPL32) in each grade of disease compared to normal. Full data set are shown in
Supplementary Table S2.
TABLE 1 | Differentially expressed characterized genes comparing grade 3 and normal valves with high stringency criteria (FDR Q-value < 0.1).
Gene symbol Description Fold change Gene symbol Description Fold change
NT5E 5-nucleotidase, ecto (CD73) −2.93 ACYP2 Acylphosphatase 2, muscle type 1.63
TANC2 Tetratricopeptide repeat, ankyrin repeat and
coiled-coil containing 2
−1.72 BNC2 Basonuclin 2 1.82
CCDC65 Coiled-coil domain containing 65 −1.69 NOV Nephroblastoma overexpressed 1.87
ENPP2 Ectonucleotide
pyrophosphatase/phosphodiesterase 2
−1.64 CDKN2B Cyclin-dependent kinase inhibitor 2B (p15,
inhibits CDK4)
1.94
LOC 102152842 Zinc finger protein 512-like −1.51 PLCXD3 Phosphatidylinositol-specific phospholipase
C, X domain containing 3
2.98
LOC 480571 Septin-4 1.51 CDKN2A Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
5.34
UBTD1 Ubiquitin domain containing 1 1.55 LRRN1 Leucine rich repeat neuronal 1 6.1
FAM174A Family with sequence similarity 174,
member A
1.58 CDKN2A Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
7.79
Genes appearing more than once were represented by more than one probe set on the array.
with similar themes to those seen without FDR correction
(Supplementary Table S12 and Supplementary Figure S6).
Dissected Valve Analysis
Seven Whitney grade 2 valves were dissected into normal and
diseased areas. As diseased areas were always at the leaflet edge,
four additional normal valves were similarly dissected to control
for normal differences between the edge and central parts of
the valve and examined using RT-qPCR alone. Dogs were aged
1–6 years (mean 4 years) and included six breeds with eight males
and three females. RNA from all diseased samples was deemed
acceptable for the microarray analysis. PCA and Graphia Pro
1.4 sample-to-sample correlation identified clustering differences
between normal and diseased regions of the diseased valves, but
also some differences between normal whole valves and grade 2
normal region samples (Figure 5).
RT-qPCR of 10 selected genes was again used for microarray
validation, and also to examine expression in region-matched
dissected areas of normal valves (Supplementary Table S1).
When comparing diseased and normal regions of the same grade
2 valves all genes were significantly altered in the same manner
as detected by microarray (P-value< 0.05). For the non-diseased
region matched to samples from similar regions in normal valves
no significant differences were detected by RT-qPCR for any of
the 10 genes examined.
Comparing normal and diseased regions from the dissected
valves, 289 genes (119 up-regulated, 170 down-regulated)
were differentially expressed (>1.5 or <1.5-fold change,
FDR adjusted q-value < 0.05, > 2.8 log2 signal intensity)
(Supplementary Table S13). Comparing the normal region
dissected from diseased valves to normal whole valve,
202 genes were differentially expressed (157 up, 45 down)
(Supplementary Table S14). When comparing the level of
similarity between these two data-sets (total of 472 DEGs),
19 were shared, with only three having the same direction of
fold change (LPAR3, CLEC5A, and WISP1). 41 DEGs were
shared between the dissected diseased region, the grade 3 and
the grade 4 datasets, with the same direction of change and
comparable fold changes, except for FGL1 which changed
in the same direction but in different proportions. Most of
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TABLE 2 | Differentially characterized expressed genes between grade 4 and normal valves with high stringency criteria (FDR Q-value < 0.1).
Gene symbol Description Fold change Gene symbol Description Fold change
NKAIN2 Na+/K+ transporting ATPase interacting 2 −3.68 KCNQ5 Potassium channel, voltage gated KQT-like
subfamily Q, member 5
−1.71
CILP Cartilage intermediate layer protein,
nucleotide pyrophosphohydrolase
−3.64 SLC1A3 Solute carrier family 1 member 3 −1.67
NT5E 5-nucleotidase, ecto (CD73) −2.99 PDGFRL Platelet-derived growth factor receptor-like −1.65
TMEFF2 Transmembrane protein with EGF-like and
two follistatin-like domains 2
−2.73 SNTB1 Syntrophin, beta 1 −1.63
ADCYAP1 Adenylate cyclase activating polypeptide 1
(pituitary)
−2.65 CACNA2D1 Calcium channel, voltage-dependent, alpha
2/delta subunit 1
−1.6
WIF1 WNT inhibitory factor 1 −2.6 MPP6 Membrane protein, palmitoylated 6 −1.59
MIR218-1 MicroRNA mir-218-1 −2.6 SCARA5 Scavenger receptor class A, member 5 −1.59
KCNQ5 Potassium channel, voltage gated KQT-like
subfamily Q, member 5
−2.07 TYW3 tRNA-yW synthesizing protein 3 homolog −1.58
LRP1B Low density lipoprotein receptor-related
protein 1B
−2.01 MOB3B MOB kinase activator 3B −1.52
ALDH1A1 Aldehyde dehydrogenase 1 family,
member A1
−2 LOC 489911 Zinc finger protein 688-like, 785 and 764 −1.52
IGF2BP2 Insulin-like growth factor 2 mRNA binding
protein 2
−2 ERBB4 Erb-b2 receptor tyrosine kinase 4 −1.51
TMEFF2 Transmembrane protein with EGF-like and
two follistatin-like domains 2
−1.95 SRSF2 Serine/arginine-rich splicing factor 2 −1.51
CRISPLD2 Cysteine-rich secretory protein LCCL domain
containing 2
−1.93 FAM174A Family with sequence similarity 174,
member A
1.51
AFF2 AF4/FMR2 family, member 2 −1.9 CDR2 Cerebellar degeneration-related protein 2, 62
kDa
1.51
PTGFR Prostaglandin F receptor (FP) −1.86 RAI14 Retinoic acid induced 14 1.55
OVGP1 Oviductal glycoprotein 1, 120 kDa −1.85 CYR61 Cysteine-rich, angiogenic inducer, 61 1.58
SCIN Scinderin −1.84
ARGLU1 Arginine and glutamate rich 1 −1.84 LOC 479476 Arachidonate 12-lipoxygenase, 12S-type 1.59
SNTB1 Syntrophin, beta 1 −1.73 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21,
Cip1)
1.62
NOV Nephroblastoma overexpressed 1.65 BMP6 Bone morphogenetic protein 6 2.19
NME1 Non-metastatic cells 1, 1.65 KCNMB1 Potassium channel subfamily M regulatory
beta subunit 1
2.25
COL4A1 Collagen, type IV, alpha 1 1.66 ANGPT1 Angiopoietin 1 2.33
LOC 100856638 Uridine phosphorylase 1 1.68 NTRK3 Neurotrophic tyrosine kinase, receptor, type 3 2.4
ADAM22 ADAM metallopeptidase domain 22 1.7 NLGN4X Neuroligin 4, X-linked 2.51
BNC2 Basonuclin 2 1.72 LRRC3B Leucine rich repeat containing 3B 2.73
LBH Limb bud and heart development 1.77 TPM2 Tropomyosin 2 (beta) 2.83
GAP43 Growth associated protein 43 1.78 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B, 3.11
ARNTL2 Aryl hydrocarbon receptor nuclear
translocator-like 2
1.79 CDKN2A Cyclin-dependent kinase inhibitor 2A, p16 3.23
ATP8B1 ATPase, amino-phospholipid 1.82 CCL13 Chemokine (C-C motif) ligand 13 3.82
GPER1 G protein-coupled estrogen receptor 1 1.87 LRRN1 Leucine rich repeat neuronal 1 3.89
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat
and PH domain 2
1.88 SERPINE1 Serpin peptidase inhibitor, clade E member 1 4.34
MFSD2A Major facilitator superfamily domain containing
2A
1.9 CDKN2A Cyclin-dependent kinase inhibitor 2A. P16 5.07
CLEC3A C-type lectin domain family 3, member A 1.95
Genes appearing more than once were represented by more than one probe set on the array.
the additional non-shared DEGs were from similar gene
families or paralogs of shared genes, with small number of
exclusive genes associated with inflammation. For the remaining
unshared genes some were paralogs of the shared genes,
but others were associated with mitochondrial functions,
lipid processing and metabolism, RNA and DNA processing
and ubiquitination.
DAVID GO term enrichment for up- and down-regulated
genes did not identify any shared terms between the two dataset
comparisons (dissected normal vs. dissected disease regions
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FIGURE 4 | Graphia Pro 1.4 cluster optimization with MCL clustering (inflation value 2.2) of 1002 differentially expressed genes. Five largest clusters from the
optimized MCL clustering data show changes with increasing Whitney grade of disease. Cluster 1, 233 genes; Cluster 2, 206 genes; Cluster 3, 147 genes; Cluster
4, 96 genes; Cluster 5, 80. Average expression values across the cluster are shown.
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TABLE 3 | Summary of the top three upstream regulators associated with the
differentially expressed genes lists for each grade of disease compared to normal,






Grade 1 P2RY2 GPCR 0.0007
Lithium Chemical drug 0.00124
Bucladesine Chemical toxicant 1.131 0.00167
Grade 2 Mma_DMAG Chemical 0.00067
TNF Cytokine 0.826 0.00089
HOXB13 Transcription regulator 0.00122
Grade 3 TGFβ1 Growth factor 1.316 3.01E-22
TNF Cytokine 2.361 8.03E-18
LPS Chemical drug 3.874 3.00E-15
Grade 4 TGFβ1 Growth factor 2.589 6.22E-18
TNF Cytokine 3.313 1.17E-14
IFNG Cytokine 3.248 3.57E-14
Dissected TNF Cytokine 2.589 7.54E-06
TGFβ1 Growth factor 0.926 1.79E-19
IFNγ Cytokine 2.233 2.19E-18
For each upstream regulator, the molecule type, Z-score (level of activation) and
P-value are shown.
FIGURE 5 | Graphia Pro 1.4 sample-to-sample correlation (r = 0.9) of
transcriptomic profiling data from dissected “normal” and dissected
“diseased” regions from grade 2 valves, and whole normal valve (grade 0),
illustrating gene clustering differences; whole normal valve samples – red,
grade 2 normal region – blue and grade 2 diseased region – yellow. Edge color
represents degree of correlation (red being stronger and blue being weaker).
and normal dissected vs. normal whole valve), with normal
dissected vs. normal whole valve analysis showing much weaker
associations to GO terms (Supplementary Table S15). The
dissected normal vs. dissected disease region analysis identified
up-regulation of GO terms associated with inflammation
and immune response and down-regulation of ECM terms.
IPA identified hepatic fibrosis/hepatic stellate cell activation
being the most significantly up-regulated canonical pathway
(Supplementary Table S16). 2156 molecules were associated
with the normal and diseased dissected region datasets, and
290 molecules with the normal dissected and normal whole
valve dataset (P < 0.05). TNF, TGFβ1 and IFNγ were the
top up-stream regulators for the dissected valve data set,
but TGFβ1 signal intensity was at least 10 times that for
TNF and IFNγ (Supplementary Figure S7). Study of the
clusters resulting from network analysis identified the disease
and function annotations for both datasets, with most terms
associated with connective tissue, cell signaling and development
(Supplementary Table S17 and Supplementary Figure S8).
Microarray results were validated by RT-qPCR (Supplementary
Table S18).
DISCUSSION
In the current study we report changes in the canine myxomatous
mitral valve transcriptome in terms of its temporal and spatial
pattern. We have identified the differential gene expression
profile associated with age-dependent disease severity (temporal
pattern) is progressive with the highest number and strongest
association detected in late stage disease. We anticipated that
whole valve gene changes in early stage disease (grades 1 and 2)
might be minimal, but by examining diseased areas in grade
2 valves (spatial pattern) we have identified genes and GO
terms shared between the early and the later stages of disease.
Pathway analysis of these five disease gene datasets has identified
TGFβ signaling as the dominant pathway, with further possible
contributions from inflammation and immune-related pathways,
such as TNF and IFNγ.
In the whole valve analysis FDR correction excluded a large
number of DEGs, particularly in early stage disease samples, but
the relative levels and direction of change were validated by RT-
qPCR for selected genes. In the two other canine transcriptomic
studies 229 and 591 DEGs were identified with FDR correction,
but all these samples compared grade 4 valves to normal valves.
In the five human transcriptomic studies of non-syndromic
mitral valve diseases, two did not use an FDR correction, two
used unconventional FDR and one used an FDR correction of
Q-value < 0.1 (Hulin et al., 2012; Sainger et al., 2012; Thalji
et al., 2015; Greenhouse et al., 2016; Driesbaugh et al., 2018).
Since MMVD pathology develops in a localized manner the
lack of differential expression in grades 1 and 2 whole valve
samples was expected, as the gene expression pattern of the
normal tissue would dampen that seen in the adjacent diseased
areas. This confounding factor was accounted for by using
the dissected valve approach and subsequently 289 DEGs were
identified (comparing normal and diseased region of grade 2
valves) after FDR correction.
Of the 1002 genes differentially expressed in at least one grade
of disease, 125 DEGs were shared with those reported by Lu
and others, and included genes such as HTR2B, CDKN1A and
BMP6, which were also differentially expressed in the study by
Oyama and others (Oyama and Chittur, 2006; Lu et al., 2015b).
In the report by Lu et al. (2015b), which only included CKCSs
(n = 4) in the disease group, TGFβ, IFNG and TNF were in
the group of the top 10 up-steam regulators identified, as well
as other inflammation-associated molecules. In the earlier study
by Oyama and Chittur (2006), where the disease group (n = 4)
consisted of three different breeds, minimal gene enrichment
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analysis was undertaken and no up-stream regulators were
reported. Surprisingly, the current study is the first to identify
by transcriptomic profiling up-regulation of ACTA2 (encoding
αSMA) in either canine or human diseased valves. ACTA2/αSMA
is a hallmark of valve interstitial cell (VIC) activation and valve
endothelial cell (VEC) endothelial-to-mesenchymal transition
(EndoMT) in MMVD and has been reported previously using
IHC and RT-qPCR to be up-regulated in a disease-severity-
dependent manner (Rabkin et al., 2001; Liu et al., 2007; Disatian
et al., 2008; Hulin et al., 2012; Lu et al., 2015a,b). For the
dissected grade 2 valves similar hallmark DEGs were identified
in the diseased samples including ACTA2 and HTR2B. While
the transcriptome of the normal whole valve and normal region
of the dissected valve were different, the DEGs did not include
any disease hallmark genes. Nevertheless, the data suggests that
even in early stage disease ostensibly normal areas might be being
impacted by pathological changes in adjacent diseased areas.
The primary aim of this study was to identify gene and
pathway transcriptional changes that contribute to disease
development and are not simply a consequence of developing
valve pathology. Gene enrichment analysis of whole valves
identified proteinaceous extracellular matrix (genes down-
regulated in disease), and inflammatory response and positive
regulation of the ERK1/2 cascade (up-regulated genes), most
noticeably in grades 3 and 4 valves. For dissected valves the
similar up-regulation of immune-related and down-regulation
of proteinaceous extracellular matrix genes indicate shared core
pathway changes are present throughout the entire time-course
of disease development. The dysregulation of some aspects of the
extracellular matrix is to be expected since there is accumulation
of proteoglycans and glycosaminoglycans and disorganization of
the collagen matrix in MMVD (Kern et al., 2010; Dupuis et al.,
2011; Hulin et al., 2013). For example, genes highlighted in this
GO term included ADAMTS5, 9, and 19. MMVD development,
typified by accumulation of proteoglycans, is found in ADAMTS5
null mice, and down-regulation of ADAMTS5 and ADAMTS19
have been reported previously in the canine and human MMVD
transcriptome (Dupuis et al., 2011; Sainger et al., 2012; Lu
et al., 2015b; Thalji et al., 2015). The up-regulation of immune
responses and the ERK1/2 cascade is a finding that has been
partially reported in the two previous canine transcriptomic
studies (Oyama and Chittur, 2006; Lu et al., 2015b). However,
while inflammatory cells have been reported in diseased human
mitral valves and in an Axin2 knockout mouse model of MMVD,
there are no changes in inflammatory cell numbers in diseased
canine valves (Thalji et al., 2015; Lu et al., 2016; Hulin et al.,
2018). The transition of VICs to an activated myofibroblast
phenotype likely causes release of cytokines and other immune-
related factors, and ERK1/2 signaling has been shown to be
involved in this phenotypic transition and the increase in αSMA
expression (Liu et al., 2007; Hutcheson et al., 2013; Busca et al.,
2016; Rutkovskiy et al., 2017). The ERK1/2 cascade is also a
downstream signaling component of both non-canonical TGFβ
signaling and 5HT signaling, both of which have been implicated
in MMVD (Connolly et al., 2009; Driesbaugh et al., 2018).
Genes that showed a more gradual up-regulation during
disease progression were associated with GO terms such as
metalloendopeptidase activity, stem cell differentiation and heart
development. The up-regulation of some metalloendopeptidase
genes in parallel with the down-regulation of extracellular matrix
genes is likely related to the extracellular matrix remodeling
and consequent need to degrade matrix proteins, fundamental
to the disease process. For example, the down-regulation of
ADAMTS5 would results in the accumulation of the proteoglycan
aggrecan, while the up-regulation of elastase-encoding MMP12
would contribute to the elastin disorganization and cleavage
and as well as facilitate EndoMT, all recognized features of
MMVD (Markby G. et al., 2017; Markby G. R. et al., 2017). Up-
regulation of the heart development pathway can also be expected
to contribute to the disease phenotype through the activation
of developmental pathways, such as EndoMT (Armstrong and
Bischoff, 2004; Hinton and Yutzey, 2011; Lu et al., 2015a,b).
The application of transcriptomic cluster analysis allowed
identification of groups of genes with similar expression patterns
associated with disease-relevant GO-terms that otherwise would
be difficult to identify if analysis relied exclusively on single
gene changes. Furthermore, cluster analysis showed that DEGs
and associated GO terms altered in late-stage disease were
progressively changing over the entire course of disease
development, and so these changes are likely to be causal
and not consequential. This is fundamentally important if the
pathogenesis of MMVD is to be understood. While there are
no MMVD-specific named pathways, IPA identified various
interesting and relevant pathways associated with disease and at
different stages. Hepatic fibrosis/hepatic stellate cell activation
was the top canonical pathway for grades 3 and 4 disease
samples, and the most important in the dissected grade 2
valve analysis. It is also the top pathway induced in normal
canine cultured valve interstitial cells treated with TGFβ1 (Tan
et al., 2019). Activated hepatic stellate cells are the source
of extracellular matrix remodeling following liver injury and
the association with the MMVD transcriptome reflects the
destabilization and remodeling of the matrix characteristic of
the disease (Eng and Friedman, 2000; Tsuchida and Friedman,
2017). The identification of TGFβ1 and TNF as important
upstream regulators fits with this pathway, and with other
immune-associated responses identified in the DAVID GO
term analysis (Bataller and Brenner, 2005; Yang et al., 2005;
Lammermann and Germain, 2014). Both TGFβ1 and TNF share
many downstream targets making distinguishing which is most
important in disease pathogenesis difficult. However, TGFβ1
appears to have the strongest associations with the disease.
The baseline gene expression of TGFβ1 was approximately 10
fold that for TNF and IFNγ. In addition, cultured VICs have
been shown to secrete much higher levels of TGFβ1 than TNF
and IFNγ, and TGFβ1 is secreted at a significantly higher
levels in activated VICs compared to quiescent cells (Tan et al.,
2019). TGFβ signaling has been previously implicated in the
development of MMVD in the dog and human and TGFβ1
transitions quiescent VICs to activated myofibroblasts, which
can be reversed by antagonizing the TGFβ receptor complex
(Black et al., 2005; Liu et al., 2007; Rutkovskiy et al., 2017;
Tan et al., 2019). Increased TGFB1 and TGFβ2 gene expression
and increased phosphorylated SMAD2/3 have been reported
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in canine and human MMVD (Surachetpong et al., 2013;
Moesgaard et al., 2014). Considering the extensive fibrosis seen in
end-stage Barlow’s Disease, the increased TGFβ gene expression
in the human valve transcriptome likely reflects contributions
from both fibrosis and myxomatous degeneration (Hulin et al.,
2012; Hagler et al., 2013; Thalji et al., 2015). The reason why
the dog valve does not develop end-stage disease fibrosis is
unknown, but comparative studies would be useful to investigate
the underlying signaling pathways that control this end-stage
outcome. Overall, the data from this and previous studies suggest
TGFβ signaling, possibly interacting with inflammation-related
pathways, is central to the pathogenesis of MMVD, both in terms
of initiation and continuing myxomatous degeneration.
The manner in which aberrant TGFβ signaling might
control myxomatous degeneration, without initiating fibrosis is
unknown. Release of ECM bound latent-TGFβ1 can be initiated
by a wide range of triggers including stretch, tensile and shear
stress, reactive oxygen species, thrombospondin, thrombin and
activating of the 5HT signaling pathway (Zhang, 2018). Once
released from latent bound stores TGFβ1 would be expected
to transition quiescent VICs in the valve stroma to activated
myofibroblasts, which will then initiate matrix remodeling.
This effect of TGFβ1 has been shown in cell culture and
TGFβ antagonism can revert activated myofibroblasts to a
quiescent phenotype suggesting potential therapeutic targets for
the management of valve pathology (Tan et al., 2019). While such
activation likely controls normal valve matrix organization and
repair, sustained activation might lead to valve pathology and the
myxomatous degeneration typical of the disease.
Network analysis found that, in contrast to grades 3 and 4,
the genes differentially expressed in grades 1 and 2 disease did
not associate strongly with cardiovascular or tissue development
functions. This suggests these functions, such as those involved
in EndoMT, are more relevant to late stage disease, and so should
be considered a consequence rather than a primary initiator
of myxomatous degeneration. Activation of EndoMT has been
identified in late-stage diseased canine valve, and likely then
contributes to ongoing valve degeneration (Lu et al., 2015a).
The association of functions of cell cycle or cell development
with all grades likely relates to the proliferation and transition
of VICs into activated myofibroblasts as a constant feature
of disease development, and grade-dependent change in cell
type, distribution and numbers has been confirmed in dogs by
immuno-histochemistry (Han et al., 2008; Blake et al., 2019).
Comparing canine and human microarray data is constrained
by a range of caveats outlined earlier. For the data reported by
Thalji et al. (2015), from confirmed BD patients, 127 DEGs were
shared with the dog data and of these only 50 had the same
direction of change (Thalji et al., 2015). As acknowledged in
that report, tissue sampling was not optimal since it depended
on surgical decision during valve repair, and normal samples
were from transplant recipient patients. With disease samples
having extensive fibrosis it is not surprising the human array data
included significant up-regulation of a range of genes associated
with fibrosis. While similar activation of pro-fibrotic pathways
are not seen in the dog valve, the canine valve transcriptome
confirms TGFβ signaling is also important in the development of
myxomatous degeneration. Since fibrosis and the lack of suitable
normal and early-stage disease samples are major confounding
factors for human MMVD research, the dog data may give some
insight into the pathogenesis of myxomatous degeneration in
human mitral valvulopathies.
CONCLUSION
In conclusion, despite differences in the total number of
DEGs identified as canine MMVD pathology progresses
over a lifetime, disease initiation, and progression appears
to be primarily dependent on changes in TGFβ signaling.
This is the first description of the temporal and spatial
expression of gene changes associated with naturally occurring
myxomatous degeneration in any species. Other signaling
pathways likely contribute to disease pathogenesis over time,
with some becoming involved only at the stage of advanced
disease. The factors that trigger the development of valve
myxomatous degeneration are still unknown, but aberrant TGFβ
signaling appears to initiate and perpetuate the valve pathology
characteristic of this disease in the dog. Studies are now required
to identify the important down-stream components of the TGFβ
signaling pathway implicated in myxomatous degeneration.
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